Fig. 1: Investigation of best-performing molecular markers for overt relapse. | Blood Cancer Journal

Fig. 1: Investigation of best-performing molecular markers for overt relapse.

From: Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation

Fig. 1

A JAK2-MRD detection rate during 1 year of follow-up. B Comparison of JAK2-MRD VAF between relapsed and unrelapsed patients at different time points. C ROC curves of the JAK2-MRD VAF and JAK2-MRD ratio at D100. The JAK2-MRD VAF at D100 (dotted line) showed an AUC value of 0.877 and an optimal threshold of 0.021% with 100% sensitivity and 70% specificity (P < 0.001). The JAK2-MRD ratio at D100 (solid line) showed the best discriminative power for overt relapse (AUC: 0.983) at an optimal threshold of 2.877% with 100% sensitivity and 91.3% specificity (P < 0.001). D and E MC (donor chimerism <95%) rates by NGS and STR during 1 year of follow-up. F and G Comparison of donor chimerism measured by NGS and STR according to the over-relapse occurrences at different time points. Significant difference in the donor chimerism between the relapsed and unrelapsed patients was found in only NGS-chimerism at D180. H NGS-chimerism at D180 AUC value of 0.840 and optimal threshold of 76.63% with 60% sensitivity and 100% specificity (P = 0.001), but I STR-chimerism D180 showed no significant AUC values (P = 0.073). VAF variant allele frequency, ROC receiver operating characteristic, AUC area under the curve, MC mixed chimerism, CC complete chimerism, NGS next-generation sequencing, STR short tandem repeat.

Back to article page